Skip to content
logo MSD Oncology Clinical Trials
  • Homepage
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Gastric
    • Gynaecologic
    • Haematological
    • Head and Neck
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Oesophageal
    • Paediatric
    • Prostate
    • Solid Tumours
  • About
  • Common Questions
  • For HCPs
  • English (AU)
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Study Keyword: Cytotoxic T-lymphocyte-associated Protein 4

Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.

The goal of substudy 02B is to evaluate the safety and efficacy of investigational treatment arms in participants with 1L advanced melanoma and to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/pembrolizumab monotherapy.

Study Keyword: Cytotoxic T-lymphocyte-associated Protein 4

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line Advanced Melanoma

March 10, 2022

By Support_Clique

Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of

logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility
  • Contact Us

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Merck Sharp & Dohme (Australia) Pty Limited. Level 1 - Building A, 26 Talavera Road, Macquarie Park, NSW 2113
AU-NON-00575 – December 2022

Accessibility

Accessibility